H.C. Wainwright analyst Edward White lowered the firm’s price target on Curis to $6 from $9 and keeps a Buy rating on the shares. The analyst slightly pushed back launch expectations for emavusertib and took into account the dilution associated with the recent capital raise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRIS: